LENZ Therapeutics (LENZ) had the highest return in Q1 2024 by a small-cap US stock, returning 1,175.1%.

ASSET	QUARTER	% RETURN
LENZ Therapeutics (LENZ)	Q1 2024	1,175.05%
Root (ROOT)	Q1 2024	486.18%
Dave (DAVE)	Q1 2024	355.71%
Sezzle Inc Common Stock (SEZL)	Q1 2024	302.33%
Arcutis Biotherapeutics (ARQT)	Q1 2024	212.62%
Destiny Tech100 (DXYZ)	Q1 2024	203.03%
Sonida Senior Living (SNDA)	Q1 2024	198.85%
Dianthus Therapeutics (DNTH)	Q1 2024	191.8%
Nyxoah (NYXH)	Q1 2024	190.73%
Praxis Precision Medicines (PRAX)	Q1 2024	174.37%
Katapult Holdings Equity Warrants Exp 09 June 2026 (KPLTW)	Q1 2024	167.57%
Neurogene (NGNE)	Q1 2024	162.64%
Stoke Therapeutics (STOK)	Q1 2024	161.63%
Logistic Properties of the Americas (LPA)	Q1 2024	160.16%
Mind Medicine (MNMD)	Q1 2024	154.05%
Trevi Therapeutics (TRVI)	Q1 2024	153.68%
Sana Biotechnology (SANA)	Q1 2024	146.31%
Chromadex (CDXC)	Q1 2024	145.07%
Nuvation Bio (NUVB)	Q1 2024	142.67%
Y mAbs Therapeutics (YMAB)	Q1 2024	141.25%
Codere Online US (CDRO)	Q1 2024	140.17%
Intuitive Machines (LUNR)	Q1 2024	137.64%
Mesoblast (MESO)	Q1 2024	131.94%
D-Wave Quantum (QBTS)	Q1 2024	131.82%
Immunome (IMNM)	Q1 2024	128.52%

Small-cap stocks are treated as having a market cap between $300M and $2B.